N- (4- fluorophenylsulfonyl)- L- valyl- L- leucinal

06/01/2004 - "This degree of cataract was reduced by approximately 40%, when SJA6017 (final concentration 0.8 microM) was included in the extralenticular medium, suggesting that the Ca2+-mediated activation of calpains may be involved in the observed opacification. "
12/01/2005 - "Cataract lambs treated with SJA6017 eyedrops over a period of 4 months showed significantly smaller cataracts in the left treated eye over the right untreated eye. "
12/01/2005 - "The calpain inhibitor SJA6017 was applied to the left eye of cataract lambs, leaving the right eye as an untreated control. "
04/01/2001 - "Systemic SJA6017 was taken up by the lens, and SJA6017 ameliorated in vivo selenite cataract formation. "
10/24/1997 - "These results suggested that SJA6017 is a reversible and cell-permeable calpain inhibitor which may possess great efficacy against calcium-induced models of cataract."

10/01/2008 - "Therapeutic efficacy of SJA6017, a calpain inhibitor, in rat spinal cord injury."
10/01/2008 - "We evaluated the neuroprotective effects of SJA6017 (a calpain inhibitor) and measured functional recovery in a rat spinal cord injury model. "

07/19/2005 - "Calpain inhibitor SJA6017 may have potential for testing as a therapeutic agent against retinal pathologies such those caused by glaucoma, although future studies such as testing in in vivo animal models are required."

02/01/2002 - "The purpose of the present study was to further establish the direct involvement of calpain in hypoxia-induced damage by administering calpain inhibitor SJA6017 to oxygen-starved, cultured retinas. "

07/01/2000 - "Moreover, the calpain inhibitor SJA6017 protected the reduction of cell density in the ganglion cell layer after ischemia-reperfusion. "
07/01/2000 - "Effect of a calpain inhibitor SJA6017 was histologically tested in retinal injury after ischemia-reperfusion. "
12/01/2006 - "An aldehyde-based calpain inhibitor, SJA6017 (1), was effective following oral administration in a rat retinal ischemia model but had low oral bioavailability. "